[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sacro-iliac-joint-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sacro-iliac-joint-pain":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,76,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100636427","posterior-inferior-intra-articular-cortical-piercing-titanium-implant-for-sacroiliac-joint-fusion-evaluation-of-safety-and-effectiveness-outcomes-100636427",false,"NCT07565545","Posterior-Inferior Intra-articular Cortical Piercing Titanium Implant for Sacroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes","Posterior-Inferior Intra-articular Cortical PiERcing Titanium Implant for SaCroiliac Joint Fusion: Evaluation of Safety and Effectiveness Outcomes","PIERCE","Inclusion Criteria:\n\n1. Age \\> 21 years.\n2. Patient has chronic lower back pain (≥6 months) refractory to non-surgical care.\n3. Diagnosis of sacroiliac joint dysfunction (degenerative sacroiliitis or SIJ disruption) and scheduled to be treated with INTRA Ti.\n4. Patient has SIJ pain of at least 5 on a 0-10 numeric rating scale (NRS) prior to procedure.\n5. Participant has signed study-specific informed consent form.\n\nExclusion Criteria:\n\n1. ASA score 4 or 5.\n2. Severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture.\n3. Other known sacroiliac pathology such as: inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondyloarthropathy), tumor, infection, acute fracture.\n4. Current diagnosis of cluneal neuralgia.\n5. Previous SIJ implant placement, including allograft, on the treated (index) side.\n6. Anatomic anomalies\u002Fdefects that would preclude safe and\u002For biomechanically acceptable device placement.\n7. History of recent (\\\u003C1 year) major trauma to pelvis.\n8. Previously diagnosed or suspected severe osteoporosis (defined as prior T-score \\\u003C -2.5 or history of osteoporotic fracture).\n9. Chronic rheumatologic condition (e.g., rheumatoid arthritis).\n10. Current diagnosis of fibromyalgia.\n11. Known allergy to titanium or titanium alloys.\n12. Current local or systemic infection that raises the risk of surgery.\n13. Patient currently receiving or seeking worker's compensation, disability remuneration, and\u002For involved in injury litigation.\n14. Currently pregnant or planning pregnancy in the next 2 years (self-reported).\n15. Patient is a prisoner or a ward of the state.\n16. Known or suspected active drug or alcohol abuse, including opioids\n17. Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation.","ALL","21 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate outcomes in patients treated with iFuse INTRA Ti for chronic SI joint pain.",[25,26,27,28,29,30],"Sacro Iliac Joint Pain","Sacro-iliac Joints","Sacroiliac Disorder","Sacroiliac Joint Dysfunction","Sacroiliac Joint Disruption","Degenerative Sacroiliitis",[32,33,34],"sacroiliac fusion","SI-BONE","INTRA Ti","NOT_YET_RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":21},"2026-09",{"date":43,"type":21},"2029-09",{"name":45,"class":46},"SI-BONE, Inc.","INDUSTRY",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100633388","additional-effects-of-mulligan-mobilization-with-movement-along-with-core-strengthening-exercises-in-postpartum-females-with-sacroiliac-joint-dysfunction-100633388","NCT07526038","Additional Effects of Mulligan Mobilization With Movement Along With Core Strengthening Exercises in Postpartum Females With Sacroiliac Joint Dysfunction","Inclusion Criteria:\n\n* Postpartum females(both normal delivery \\& C-section) aged 20-40 years\n* Parity level: Multiparous\n* Duration: 6 weeks to 6 months postpartum\n* At least three Positive SIJ provocation tests (e.g., stork test, compression, distraction, thigh thrust, Ganslen's and sacral thrust)\n\nExclusion Criteria:\n\n* Pelvic fractures or recent surgery\n* Neurological or rheumatologic disorders\n* Inability to participate in active exercise or manual therapy due to medical or psychological reasons","FEMALE","20 Years","40 Years",{"count":57,"type":21},48,"INTERVENTIONAL",[60],"NA","This study aims to evaluate the combined effectiveness of Mulligan mobilization and core strengthening exercises in managing postpartum sacroiliac joint dysfunction (SIJD). Postpartum SIJD is a common condition resulting from biomechanical and hormonal changes during pregnancy, often leading to pelvic instability and pain. Mulligan mobilization, a manual therapy technique, aims to correct joint alignment and restore pain-free movement. For the SIJ, Mulligan MWM aims to correct subtle positional faults or movement restrictions that may cause pain and dysfunction-especially common postpartum due to ligamentous laxity, hormonal changes, and altered biomechanics.The core muscles provide stability to the pelvis and lumbar spine. When these muscles are weak or imbalanced, it can lead to increased strain on the SIJ, contributing to pain and dysfunction. Strengthening the core improves load transfer through the pelvis and enhances neuromuscular control, thereby reducing SIJ stress and symptoms. Core strengthening exercises enhances outcomes by targeting both mechanical alignment and muscular stability. Core strengthening exercises target muscles that support pelvic stability, including the transverse abdominis and pelvic floor. The study hypothesizes that integrating Mulligan mobilization with core strengthening may provide superior outcomes in pain reduction, joint function, and overall quality of life compared to core exercises alone.",[25,63,64],"Post Partum","Strength Training","RECRUITING","2026-05-18",{"date":68,"type":39},"2026-05-20",{"date":68,"type":21},{"date":71,"type":21},"2026-07-15",{"name":73,"class":74},"Foundation University Islamabad","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":75},"100631283","prp-injection-into-the-sacroiliac-joint-after-ipsilateral-tha-effects-on-early-recovery-and-function-sij-tha-randomized-trial-100631283","NCT07498660","PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial)","Effect of Platelet-Rich Plasma Injection Into the Sacroiliac Joint After Ipsilateral Total Hip Arthroplasty on Early Rehabilitation and Patient Function: A Randomized Trial (SIJ-THA Trial)","Inclusion Criteria:\n\n* primary osteoarthritis of the hip;\n* qualification for elective total hip arthroplasty (THA);\n* age ≥45 years;\n* written informed consent;\n* ability to understand Polish.\n\nExclusion Criteria:\n\n* prior surgical treatment of the hip or sacroiliac joint;\n* malignancy;\n* developmental dysplasia of the hip;\n* rheumatologic diseases (rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis);\n* neurological or psychiatric disorders;\n* allergy to local anesthetics.","45 Years",{"count":85,"type":21},60,[60],"The study is an interventional, randomized, open-label (non-blinded), placebo-controlled trial. Preoperatively, patients scheduled for primary total hip arthroplasty (THA) will undergo a clinical examination in the Orthopaedic Department. Clinical tests will be performed to confirm sacroiliac joint (SIJ) dysfunction on the operated side. In addition, low-dose computed tomography (CT) will be used to assess structural changes in the SIJ.\n\nAll patients will complete patient-reported outcome measures related to the hip joint, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Harris Hip Score (HHS), as well as SIJ-related assessments, including the Oswestry Disability Index (ODI). Pain intensity will be assessed using the Visual Analogue Scale (VAS).\n\nFollowing THA, patients will be randomly allocated into two groups during their hospital stay. In the intervention group, platelet-rich plasma (PRP) will be injected into the sacroiliac joint, whereas the control group will receive an injection of normal saline. All injections will be performed in the operating theatre.\n\nAt discharge, patients will be scheduled for follow-up visits at 2, 6, and 12 weeks postoperatively. At each follow-up, patient-reported outcomes will be collected, including WOMAC and HHS for hip function, ODI for SIJ-related disability, and VAS for pain assessment of both the hip and sacroiliac joint.",[89,25,90,91],"Osteoarthitis","Hip Arthroplasty, Total","Sacro-Iliac Spondylosis","2026-03-23",{"date":94,"type":39},"2026-03-27",{"date":96,"type":21},"2026-04-01",{"date":98,"type":21},"2028-03-31",{"name":100,"class":74},"Medical University of Warsaw",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":58,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":75},"100522321","early-phase-1-ketorolac-versus-corticosteroid-injections-for-sacroiliac-joint-pain-100522321","NCT06081101","Ketorolac Versus Corticosteroid Injections for Sacroiliac Joint Pain","Ultrasound Guided Sacroiliac Joint Injections With Ketorolac Versus Corticosteroid: A Prospective Non-inferiority Study","Inclusion Criteria:\n\n* SI joint pain for at least 3 months\n* Age greater than 18\n* Must have at least 3 special tests positive for SI joint pain on physical exam\n\nExclusion Criteria:\n\n* Previous back surgery\n* Radicular leg pain\n* Discogenic pain\n* Myofascial pain syndrome\n* Depression\n* Systemic infection or localized infection at anticipated needle entry sites\n* Cognitive impairment preventing informed consent or accurate collection of data\n* Patient allergic to medication used\n* NSAID contraindications including:\n* Gastrointestinal bleeds\n* Renal failure\n* Symptomatic congestive heart failure\n* Cirrhosis",true,"18 Years",{"count":111,"type":21},20,[113],"EARLY_PHASE1","This study will contribute to the current literature that have compared joint injections with steroid versus ketorolac providing evidence for the use of ketorolac for SI joint pain. Currently steroid is the clinical standard for joint injections, however with repetitive use, steroid injections can damage the joint. Ketorolac is an alternative anti-inflammatory medication that does not cause the same joint damage and at a cheaper cost than steroid. The investigators hypothesize that ultrasound guided SI joint injections utilizing ketorolac provide the same pain relief as corticosteroid SI joint injections measured at 2, 6 and 12 weeks post injection. This would allow more frequent injections to control pain at a decreased cost to the healthcare system.",[116],"Sacro-iliac Joint Pain","2024-11-18",{"date":119,"type":39},"2024-11-20",{"date":121,"type":21},"2025-01",{"date":123,"type":21},"2026-06",{"name":125,"class":74},"McMaster University"]